Daniel Skiest to HIV
This is a "connection" page, showing publications Daniel Skiest has written about HIV.
Connection Strength
0.355
-
Skiest DJ, Morrow P, Allen B, McKinsey J, Crosby C, Foster B, Hardy RD. It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cells/microL. J Acquir Immune Defic Syndr. 2004 Nov 01; 37(3):1351-7.
Score: 0.232
-
Cenizal MJ, Hardy RD, Anderson M, Katz K, Skiest DJ. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients. J Acquir Immune Defic Syndr. 2008 Aug 15; 48(5):567-71.
Score: 0.075
-
Glesby MJ, Watson W, Brinson C, Greenberg RN, Lalezari JP, Skiest D, Sundaraiyer V, Natuk R, Gurtman A, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine. J Infect Dis. 2015 Jul 01; 212(1):18-27.
Score: 0.029
-
Vahey MT, Wang Z, Su Z, Nau ME, Krambrink A, Skiest DJ, Margolis DM. CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway. AIDS Res Hum Retroviruses. 2008 Aug; 24(8):1047-66.
Score: 0.019